BioStem Technologies, Inc. · Exercise / conversion · Common Stock

What does this filing report?

An SEC Form 4 filing for BioStem Technologies, Inc. records an exercise / conversion involving Common Stock on October 7, 2026. The reported quantity was 250,000. The filing date is October 9, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

The amount corrects the number of shares of common stock held by the Reporting Person, which over-reported a prior vesting of restricted stock units by one share in the Form 3 filed on August 14, 2026 and the Form 4 filed on September 17, 2026 due to an administrative error.

F2

The Series A-1 Convertible Preferred Shares is convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares.

F3

The Series A-1 Convertible Preferred Shares have no expiration date.

F4

Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026.

F5

These options are fully vested and exercisable.

F6

These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

F7

These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

F8

These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

F9

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F10

These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024).

F11

These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

F12

These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.